nodes	percent_of_prediction	percent_of_DWPC	metapath
Bismuth Subsalicylate—PTGS2—Etoposide—uterine cancer	0.174	0.542	CbGbCtD
Bismuth Subsalicylate—PTGS1—Etoposide—uterine cancer	0.147	0.458	CbGbCtD
Bismuth Subsalicylate—TF—semen—uterine cancer	0.0598	0.244	CbGeAlD
Bismuth Subsalicylate—TF—exocrine gland—uterine cancer	0.0253	0.103	CbGeAlD
Bismuth Subsalicylate—Venous thrombosis—Carboplatin—uterine cancer	0.0203	0.0559	CcSEcCtD
Bismuth Subsalicylate—Skin papilloma—Progesterone—uterine cancer	0.0176	0.0486	CcSEcCtD
Bismuth Subsalicylate—Fluid overload—Carboplatin—uterine cancer	0.0176	0.0485	CcSEcCtD
Bismuth Subsalicylate—PTGS1—oviduct—uterine cancer	0.013	0.053	CbGeAlD
Bismuth Subsalicylate—Extravasation—Carboplatin—uterine cancer	0.0126	0.0346	CcSEcCtD
Bismuth Subsalicylate—TF—epithelium—uterine cancer	0.011	0.0449	CbGeAlD
Bismuth Subsalicylate—TF—uterine cervix—uterine cancer	0.0109	0.0445	CbGeAlD
Bismuth Subsalicylate—TF—renal system—uterine cancer	0.0102	0.0417	CbGeAlD
Bismuth Subsalicylate—Venous thrombosis—Medroxyprogesterone Acetate—uterine cancer	0.00966	0.0266	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Carboplatin—uterine cancer	0.00923	0.0254	CcSEcCtD
Bismuth Subsalicylate—TF—uterus—uterine cancer	0.00911	0.0371	CbGeAlD
Bismuth Subsalicylate—PTGS1—artery—uterine cancer	0.00862	0.0351	CbGeAlD
Bismuth Subsalicylate—PTGS2—artery—uterine cancer	0.00824	0.0336	CbGeAlD
Bismuth Subsalicylate—TF—female reproductive system—uterine cancer	0.00819	0.0334	CbGeAlD
Bismuth Subsalicylate—Heartburn—Medroxyprogesterone Acetate—uterine cancer	0.00757	0.0209	CcSEcCtD
Bismuth Subsalicylate—TF—female gonad—uterine cancer	0.00745	0.0304	CbGeAlD
Bismuth Subsalicylate—TF—vagina—uterine cancer	0.0074	0.0302	CbGeAlD
Bismuth Subsalicylate—TF—Differentiation Pathway—INHBA—uterine cancer	0.00579	0.0814	CbGpPWpGaD
Bismuth Subsalicylate—Lightheadedness—Progesterone—uterine cancer	0.00515	0.0142	CcSEcCtD
Bismuth Subsalicylate—TF—lymph node—uterine cancer	0.00479	0.0195	CbGeAlD
Bismuth Subsalicylate—Extravasation—Dactinomycin—uterine cancer	0.00466	0.0128	CcSEcCtD
Bismuth Subsalicylate—PTGS2—myometrium—uterine cancer	0.00398	0.0162	CbGeAlD
Bismuth Subsalicylate—Infection—Carboplatin—uterine cancer	0.00388	0.0107	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Dactinomycin—uterine cancer	0.00372	0.0102	CcSEcCtD
Bismuth Subsalicylate—Asthma—Progesterone—uterine cancer	0.00361	0.00995	CcSEcCtD
Bismuth Subsalicylate—Abdominal discomfort—Progesterone—uterine cancer	0.00346	0.00954	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Dactinomycin—uterine cancer	0.00343	0.00944	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Etoposide—uterine cancer	0.00337	0.0093	CcSEcCtD
Bismuth Subsalicylate—Pain—Carboplatin—uterine cancer	0.00334	0.00921	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Progesterone—uterine cancer	0.00328	0.00905	CcSEcCtD
Bismuth Subsalicylate—Asthma—Medroxyprogesterone Acetate—uterine cancer	0.00327	0.00901	CcSEcCtD
Bismuth Subsalicylate—PTGS1—epithelium—uterine cancer	0.00327	0.0133	CbGeAlD
Bismuth Subsalicylate—PTGS1—uterine cervix—uterine cancer	0.00324	0.0132	CbGeAlD
Bismuth Subsalicylate—Drowsiness—Progesterone—uterine cancer	0.00322	0.00887	CcSEcCtD
Bismuth Subsalicylate—PTGS1—smooth muscle tissue—uterine cancer	0.00315	0.0128	CbGeAlD
Bismuth Subsalicylate—Abdominal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.00314	0.00864	CcSEcCtD
Bismuth Subsalicylate—PTGS2—epithelium—uterine cancer	0.00312	0.0127	CbGeAlD
Bismuth Subsalicylate—PTGS2—uterine cervix—uterine cancer	0.0031	0.0126	CbGeAlD
Bismuth Subsalicylate—Body temperature increased—Carboplatin—uterine cancer	0.00309	0.00851	CcSEcCtD
Bismuth Subsalicylate—Venous thrombosis—Epirubicin—uterine cancer	0.00306	0.00842	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—AKR1C3—uterine cancer	0.00305	0.0429	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—renal system—uterine cancer	0.00303	0.0124	CbGeAlD
Bismuth Subsalicylate—Lethargy—Dactinomycin—uterine cancer	0.00301	0.0083	CcSEcCtD
Bismuth Subsalicylate—PTGS2—smooth muscle tissue—uterine cancer	0.00301	0.0123	CbGeAlD
Bismuth Subsalicylate—Weight increased—Medroxyprogesterone Acetate—uterine cancer	0.00298	0.0082	CcSEcCtD
Bismuth Subsalicylate—PTGS1—endometrium—uterine cancer	0.00293	0.0119	CbGeAlD
Bismuth Subsalicylate—Drowsiness—Medroxyprogesterone Acetate—uterine cancer	0.00292	0.00804	CcSEcCtD
Bismuth Subsalicylate—PTGS2—renal system—uterine cancer	0.0029	0.0118	CbGeAlD
Bismuth Subsalicylate—Hepatitis—Progesterone—uterine cancer	0.00289	0.00796	CcSEcCtD
Bismuth Subsalicylate—Gastric ulcer—Epirubicin—uterine cancer	0.00284	0.00782	CcSEcCtD
Bismuth Subsalicylate—PTGS1—mammalian vulva—uterine cancer	0.00283	0.0116	CbGeAlD
Bismuth Subsalicylate—Venous thrombosis—Doxorubicin—uterine cancer	0.00283	0.00779	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Etoposide—uterine cancer	0.00281	0.00774	CcSEcCtD
Bismuth Subsalicylate—PTGS2—endometrium—uterine cancer	0.0028	0.0114	CbGeAlD
Bismuth Subsalicylate—Epistaxis—Medroxyprogesterone Acetate—uterine cancer	0.00275	0.00758	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Progesterone—uterine cancer	0.00273	0.00753	CcSEcCtD
Bismuth Subsalicylate—PTGS1—uterus—uterine cancer	0.0027	0.011	CbGeAlD
Bismuth Subsalicylate—Tinnitus—Progesterone—uterine cancer	0.00269	0.00742	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Etoposide—uterine cancer	0.00269	0.00741	CcSEcCtD
Bismuth Subsalicylate—Gastric ulcer—Doxorubicin—uterine cancer	0.00263	0.00724	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Medroxyprogesterone Acetate—uterine cancer	0.00262	0.00722	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFE2L2—uterine cancer	0.0026	0.0366	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—uterus—uterine cancer	0.00258	0.0105	CbGeAlD
Bismuth Subsalicylate—Erythema—Progesterone—uterine cancer	0.00251	0.00693	CcSEcCtD
Bismuth Subsalicylate—ALB—lymph node—uterine cancer	0.00249	0.0102	CbGeAlD
Bismuth Subsalicylate—Phlebitis—Etoposide—uterine cancer	0.00248	0.00683	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Medroxyprogesterone Acetate—uterine cancer	0.00247	0.00682	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Medroxyprogesterone Acetate—uterine cancer	0.00244	0.00673	CcSEcCtD
Bismuth Subsalicylate—PTGS1—female reproductive system—uterine cancer	0.00243	0.00989	CbGeAlD
Bismuth Subsalicylate—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—AKR1C3—uterine cancer	0.00242	0.0341	CbGpPWpGaD
Bismuth Subsalicylate—Burning sensation—Epirubicin—uterine cancer	0.00237	0.00654	CcSEcCtD
Bismuth Subsalicylate—Lung disorder—Epirubicin—uterine cancer	0.00233	0.00642	CcSEcCtD
Bismuth Subsalicylate—PTGS2—female reproductive system—uterine cancer	0.00232	0.00945	CbGeAlD
Bismuth Subsalicylate—Erythema—Medroxyprogesterone Acetate—uterine cancer	0.00228	0.00628	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Medroxyprogesterone Acetate—uterine cancer	0.00223	0.00615	CcSEcCtD
Bismuth Subsalicylate—PTGS1—female gonad—uterine cancer	0.00221	0.009	CbGeAlD
Bismuth Subsalicylate—Burning sensation—Doxorubicin—uterine cancer	0.0022	0.00606	CcSEcCtD
Bismuth Subsalicylate—PTGS1—vagina—uterine cancer	0.0022	0.00895	CbGeAlD
Bismuth Subsalicylate—Lung disorder—Doxorubicin—uterine cancer	0.00216	0.00594	CcSEcCtD
Bismuth Subsalicylate—PTGS2—female gonad—uterine cancer	0.00211	0.0086	CbGeAlD
Bismuth Subsalicylate—PTGS2—vagina—uterine cancer	0.0021	0.00855	CbGeAlD
Bismuth Subsalicylate—Confusional state—Progesterone—uterine cancer	0.00207	0.0057	CcSEcCtD
Bismuth Subsalicylate—Oedema—Progesterone—uterine cancer	0.00205	0.00566	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Dactinomycin—uterine cancer	0.00204	0.00563	CcSEcCtD
Bismuth Subsalicylate—Infection—Progesterone—uterine cancer	0.00204	0.00562	CcSEcCtD
Bismuth Subsalicylate—Stinging—Epirubicin—uterine cancer	0.00204	0.00561	CcSEcCtD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—SMAD3—uterine cancer	0.00198	0.0279	CbGpPWpGaD
Bismuth Subsalicylate—Anorexia—Progesterone—uterine cancer	0.00196	0.00539	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Dactinomycin—uterine cancer	0.00193	0.00532	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Epirubicin—uterine cancer	0.00189	0.00521	CcSEcCtD
Bismuth Subsalicylate—Stinging—Doxorubicin—uterine cancer	0.00188	0.00519	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Medroxyprogesterone Acetate—uterine cancer	0.00188	0.00517	CcSEcCtD
Bismuth Subsalicylate—Oedema—Medroxyprogesterone Acetate—uterine cancer	0.00186	0.00513	CcSEcCtD
Bismuth Subsalicylate—Infection—Medroxyprogesterone Acetate—uterine cancer	0.00185	0.00509	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Progesterone—uterine cancer	0.00182	0.00503	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Progesterone—uterine cancer	0.00181	0.00498	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Progesterone—uterine cancer	0.00178	0.00492	CcSEcCtD
Bismuth Subsalicylate—Erythema—Dactinomycin—uterine cancer	0.00178	0.0049	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Medroxyprogesterone Acetate—uterine cancer	0.00177	0.00489	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Prostaglandin Synthesis and Regulation—CYP11A1—uterine cancer	0.00176	0.0247	CbGpPWpGaD
Bismuth Subsalicylate—Constipation—Progesterone—uterine cancer	0.00176	0.00484	CcSEcCtD
Bismuth Subsalicylate—Pain—Progesterone—uterine cancer	0.00176	0.00484	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Doxorubicin—uterine cancer	0.00175	0.00482	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Progesterone—uterine cancer	0.00169	0.00466	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.00165	0.00456	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.00164	0.00451	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Progesterone—uterine cancer	0.00163	0.00449	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Progesterone—uterine cancer	0.00162	0.00447	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.00162	0.00446	CcSEcCtD
Bismuth Subsalicylate—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.00159	0.00438	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Epirubicin—uterine cancer	0.00157	0.00434	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.00153	0.00422	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Epirubicin—uterine cancer	0.00151	0.00415	CcSEcCtD
Bismuth Subsalicylate—Ecchymosis—Epirubicin—uterine cancer	0.00149	0.00411	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.00148	0.00407	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.00147	0.00405	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Doxorubicin—uterine cancer	0.00146	0.00402	CcSEcCtD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—YWHAE—uterine cancer	0.00145	0.0204	CbGpPWpGaD
Bismuth Subsalicylate—Pruritus—Progesterone—uterine cancer	0.00145	0.004	CcSEcCtD
Bismuth Subsalicylate—Oedema—Dactinomycin—uterine cancer	0.00145	0.004	CcSEcCtD
Bismuth Subsalicylate—Infection—Dactinomycin—uterine cancer	0.00144	0.00397	CcSEcCtD
Bismuth Subsalicylate—PTGS1—lymph node—uterine cancer	0.00142	0.00579	CbGeAlD
Bismuth Subsalicylate—Diarrhoea—Progesterone—uterine cancer	0.0014	0.00387	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Etoposide—uterine cancer	0.0014	0.00385	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Doxorubicin—uterine cancer	0.00139	0.00384	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Prostaglandin Synthesis and Regulation—CYP11A1—uterine cancer	0.00139	0.0196	CbGpPWpGaD
Bismuth Subsalicylate—Phlebitis—Epirubicin—uterine cancer	0.00139	0.00383	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Dactinomycin—uterine cancer	0.00138	0.00381	CcSEcCtD
Bismuth Subsalicylate—Ecchymosis—Doxorubicin—uterine cancer	0.00138	0.0038	CcSEcCtD
Bismuth Subsalicylate—TF—EPHB forward signaling—NRAS—uterine cancer	0.00138	0.0194	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—lymph node—uterine cancer	0.00136	0.00553	CbGeAlD
Bismuth Subsalicylate—Dizziness—Progesterone—uterine cancer	0.00136	0.00374	CcSEcCtD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—ESR2—uterine cancer	0.00134	0.0189	CbGpPWpGaD
Bismuth Subsalicylate—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.00132	0.00363	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Progesterone—uterine cancer	0.0013	0.0036	CcSEcCtD
Bismuth Subsalicylate—Rash—Progesterone—uterine cancer	0.00129	0.00357	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Progesterone—uterine cancer	0.00129	0.00356	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Doxorubicin—uterine cancer	0.00129	0.00354	CcSEcCtD
Bismuth Subsalicylate—Headache—Progesterone—uterine cancer	0.00129	0.00354	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.00127	0.00351	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Dactinomycin—uterine cancer	0.00126	0.00348	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Etoposide—uterine cancer	0.00126	0.00347	CcSEcCtD
Bismuth Subsalicylate—Pain—Dactinomycin—uterine cancer	0.00124	0.00342	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.00123	0.00339	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Epirubicin—uterine cancer	0.00122	0.00337	CcSEcCtD
Bismuth Subsalicylate—Nausea—Progesterone—uterine cancer	0.00122	0.00336	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Epirubicin—uterine cancer	0.0012	0.00331	CcSEcCtD
Bismuth Subsalicylate—ALB—Bile acid and bile salt metabolism—AKR1C1—uterine cancer	0.0012	0.0168	CbGpPWpGaD
Bismuth Subsalicylate—Feeling abnormal—Dactinomycin—uterine cancer	0.0012	0.00329	CcSEcCtD
Bismuth Subsalicylate—TF—EPHB forward signaling—KRAS—uterine cancer	0.00119	0.0167	CbGpPWpGaD
Bismuth Subsalicylate—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.00118	0.00326	CcSEcCtD
Bismuth Subsalicylate—TF—Differentiation Pathway—VEGFA—uterine cancer	0.00118	0.0166	CbGpPWpGaD
Bismuth Subsalicylate—Rash—Medroxyprogesterone Acetate—uterine cancer	0.00117	0.00323	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.00117	0.00323	CcSEcCtD
Bismuth Subsalicylate—Headache—Medroxyprogesterone Acetate—uterine cancer	0.00117	0.00321	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Dactinomycin—uterine cancer	0.00115	0.00316	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Doxorubicin—uterine cancer	0.00113	0.00312	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—NFE2L2—uterine cancer	0.00112	0.0157	CbGpPWpGaD
Bismuth Subsalicylate—Hyponatraemia—Doxorubicin—uterine cancer	0.00111	0.00307	CcSEcCtD
Bismuth Subsalicylate—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.0011	0.00304	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.0011	0.0155	CbGpPWpGaD
Bismuth Subsalicylate—Abdominal pain upper—Epirubicin—uterine cancer	0.00109	0.00301	CcSEcCtD
Bismuth Subsalicylate—TF—EPHB forward signaling—PIK3CA—uterine cancer	0.00109	0.0153	CbGpPWpGaD
Bismuth Subsalicylate—Confusional state—Etoposide—uterine cancer	0.00106	0.00292	CcSEcCtD
Bismuth Subsalicylate—Infection—Etoposide—uterine cancer	0.00104	0.00287	CcSEcCtD
Bismuth Subsalicylate—Asthma—Epirubicin—uterine cancer	0.00103	0.00285	CcSEcCtD
Bismuth Subsalicylate—Abdominal pain upper—Doxorubicin—uterine cancer	0.00101	0.00279	CcSEcCtD
Bismuth Subsalicylate—TF—EPHB forward signaling—HRAS—uterine cancer	0.00101	0.0142	CbGpPWpGaD
Bismuth Subsalicylate—Anorexia—Etoposide—uterine cancer	0.001	0.00276	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Dactinomycin—uterine cancer	0.000992	0.00274	CcSEcCtD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—EP300—uterine cancer	0.000967	0.0136	CbGpPWpGaD
Bismuth Subsalicylate—Asthma—Doxorubicin—uterine cancer	0.000958	0.00264	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Epirubicin—uterine cancer	0.000942	0.0026	CcSEcCtD
Bismuth Subsalicylate—TF—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.000935	0.0131	CbGpPWpGaD
Bismuth Subsalicylate—Somnolence—Etoposide—uterine cancer	0.000933	0.00257	CcSEcCtD
Bismuth Subsalicylate—Drowsiness—Epirubicin—uterine cancer	0.000923	0.00254	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Dactinomycin—uterine cancer	0.000922	0.00254	CcSEcCtD
Bismuth Subsalicylate—ALB—Bile acid and bile salt metabolism—AKR1C3—uterine cancer	0.000921	0.0129	CbGpPWpGaD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—VEGFA—uterine cancer	0.000915	0.0129	CbGpPWpGaD
Bismuth Subsalicylate—Rash—Dactinomycin—uterine cancer	0.000915	0.00252	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Etoposide—uterine cancer	0.000913	0.00252	CcSEcCtD
Bismuth Subsalicylate—Pain—Etoposide—uterine cancer	0.000898	0.00247	CcSEcCtD
Bismuth Subsalicylate—Constipation—Etoposide—uterine cancer	0.000898	0.00247	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.000875	0.0123	CbGpPWpGaD
Bismuth Subsalicylate—Weight increased—Doxorubicin—uterine cancer	0.000871	0.0024	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Epirubicin—uterine cancer	0.00087	0.0024	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Overview of nanoparticle effects—CXCL8—uterine cancer	0.000866	0.0122	CbGpPWpGaD
Bismuth Subsalicylate—Feeling abnormal—Etoposide—uterine cancer	0.000865	0.00238	CcSEcCtD
Bismuth Subsalicylate—Nausea—Dactinomycin—uterine cancer	0.000862	0.00237	CcSEcCtD
Bismuth Subsalicylate—Drowsiness—Doxorubicin—uterine cancer	0.000854	0.00235	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Etoposide—uterine cancer	0.000834	0.0023	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Etoposide—uterine cancer	0.00083	0.00229	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Epirubicin—uterine cancer	0.000828	0.00228	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000818	0.0115	CbGpPWpGaD
Bismuth Subsalicylate—Epistaxis—Doxorubicin—uterine cancer	0.000805	0.00222	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—GPX3—uterine cancer	0.0008	0.0112	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet degranulation—VEGFA—uterine cancer	0.000785	0.011	CbGpPWpGaD
Bismuth Subsalicylate—Erythema multiforme—Epirubicin—uterine cancer	0.000783	0.00216	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—MAP3K4—uterine cancer	0.000773	0.0109	CbGpPWpGaD
Bismuth Subsalicylate—Tinnitus—Epirubicin—uterine cancer	0.000772	0.00213	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Doxorubicin—uterine cancer	0.000766	0.00211	CcSEcCtD
Bismuth Subsalicylate—TF—Response to elevated platelet cytosolic Ca2+—VEGFA—uterine cancer	0.000748	0.0105	CbGpPWpGaD
Bismuth Subsalicylate—Pruritus—Etoposide—uterine cancer	0.000743	0.00205	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Doxorubicin—uterine cancer	0.000725	0.002	CcSEcCtD
Bismuth Subsalicylate—Erythema—Epirubicin—uterine cancer	0.000721	0.00199	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Etoposide—uterine cancer	0.000718	0.00198	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Doxorubicin—uterine cancer	0.000715	0.00197	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Epirubicin—uterine cancer	0.000706	0.00195	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Etoposide—uterine cancer	0.000694	0.00191	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Overview of nanoparticle effects—CXCL8—uterine cancer	0.000687	0.00966	CbGpPWpGaD
Bismuth Subsalicylate—Vomiting—Etoposide—uterine cancer	0.000668	0.00184	CcSEcCtD
Bismuth Subsalicylate—Erythema—Doxorubicin—uterine cancer	0.000667	0.00184	CcSEcCtD
Bismuth Subsalicylate—Rash—Etoposide—uterine cancer	0.000662	0.00182	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Etoposide—uterine cancer	0.000661	0.00182	CcSEcCtD
Bismuth Subsalicylate—Headache—Etoposide—uterine cancer	0.000658	0.00181	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Doxorubicin—uterine cancer	0.000653	0.0018	CcSEcCtD
Bismuth Subsalicylate—ALB—Folate Metabolism—GPX3—uterine cancer	0.000647	0.00909	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—uterine cancer	0.00064	0.009	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—GPX3—uterine cancer	0.000635	0.00893	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Etoposide—uterine cancer	0.000624	0.00172	CcSEcCtD
Bismuth Subsalicylate—TF—Hemostasis—IRF1—uterine cancer	0.000607	0.00853	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—uterine cancer	0.000606	0.00851	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000602	0.00846	CbGpPWpGaD
Bismuth Subsalicylate—Confusional state—Epirubicin—uterine cancer	0.000593	0.00164	CcSEcCtD
Bismuth Subsalicylate—Oedema—Epirubicin—uterine cancer	0.000588	0.00162	CcSEcCtD
Bismuth Subsalicylate—Infection—Epirubicin—uterine cancer	0.000585	0.00161	CcSEcCtD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—AKT1—uterine cancer	0.000584	0.00821	CbGpPWpGaD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—CXCL8—uterine cancer	0.000566	0.00796	CbGpPWpGaD
Bismuth Subsalicylate—Anorexia—Epirubicin—uterine cancer	0.000561	0.00155	CcSEcCtD
Bismuth Subsalicylate—PTGS2—S1P1 pathway—VEGFA—uterine cancer	0.000558	0.00785	CbGpPWpGaD
Bismuth Subsalicylate—Confusional state—Doxorubicin—uterine cancer	0.000549	0.00151	CcSEcCtD
Bismuth Subsalicylate—Oedema—Doxorubicin—uterine cancer	0.000545	0.0015	CcSEcCtD
Bismuth Subsalicylate—Infection—Doxorubicin—uterine cancer	0.000541	0.00149	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Epirubicin—uterine cancer	0.000523	0.00144	CcSEcCtD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	0.000523	0.00735	CbGpPWpGaD
Bismuth Subsalicylate—Anorexia—Doxorubicin—uterine cancer	0.000519	0.00143	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Epirubicin—uterine cancer	0.000518	0.00143	CcSEcCtD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—GPX3—uterine cancer	0.000514	0.00722	CbGpPWpGaD
Bismuth Subsalicylate—Decreased appetite—Epirubicin—uterine cancer	0.000512	0.00141	CcSEcCtD
Bismuth Subsalicylate—Pain—Epirubicin—uterine cancer	0.000503	0.00139	CcSEcCtD
Bismuth Subsalicylate—Constipation—Epirubicin—uterine cancer	0.000503	0.00139	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—ESR1—uterine cancer	0.000487	0.00684	CbGpPWpGaD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—EP300—uterine cancer	0.000486	0.00683	CbGpPWpGaD
Bismuth Subsalicylate—Feeling abnormal—Epirubicin—uterine cancer	0.000485	0.00134	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Doxorubicin—uterine cancer	0.000484	0.00133	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Doxorubicin—uterine cancer	0.000479	0.00132	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Doxorubicin—uterine cancer	0.000473	0.0013	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Epirubicin—uterine cancer	0.000468	0.00129	CcSEcCtD
Bismuth Subsalicylate—Pain—Doxorubicin—uterine cancer	0.000466	0.00128	CcSEcCtD
Bismuth Subsalicylate—Constipation—Doxorubicin—uterine cancer	0.000466	0.00128	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Epirubicin—uterine cancer	0.000465	0.00128	CcSEcCtD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—VEGFA—uterine cancer	0.00046	0.00647	CbGpPWpGaD
Bismuth Subsalicylate—Feeling abnormal—Doxorubicin—uterine cancer	0.000449	0.00124	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Biological oxidations—CYP11A1—uterine cancer	0.000434	0.00611	CbGpPWpGaD
Bismuth Subsalicylate—Urticaria—Doxorubicin—uterine cancer	0.000433	0.00119	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	0.000432	0.00607	CbGpPWpGaD
Bismuth Subsalicylate—Body temperature increased—Doxorubicin—uterine cancer	0.00043	0.00119	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Epirubicin—uterine cancer	0.000416	0.00115	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—MTHFR—uterine cancer	0.000411	0.00577	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Vitamin B12 Metabolism—MTHFR—uterine cancer	0.000408	0.00574	CbGpPWpGaD
Bismuth Subsalicylate—Diarrhoea—Epirubicin—uterine cancer	0.000403	0.00111	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Epirubicin—uterine cancer	0.000389	0.00107	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.000386	0.00542	CbGpPWpGaD
Bismuth Subsalicylate—Pruritus—Doxorubicin—uterine cancer	0.000385	0.00106	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Epirubicin—uterine cancer	0.000374	0.00103	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Doxorubicin—uterine cancer	0.000373	0.00103	CcSEcCtD
Bismuth Subsalicylate—Rash—Epirubicin—uterine cancer	0.000371	0.00102	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Epirubicin—uterine cancer	0.000371	0.00102	CcSEcCtD
Bismuth Subsalicylate—Headache—Epirubicin—uterine cancer	0.000369	0.00102	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Doxorubicin—uterine cancer	0.00036	0.000993	CcSEcCtD
Bismuth Subsalicylate—Nausea—Epirubicin—uterine cancer	0.00035	0.000964	CcSEcCtD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	0.000348	0.00489	CbGpPWpGaD
Bismuth Subsalicylate—Vomiting—Doxorubicin—uterine cancer	0.000346	0.000954	CcSEcCtD
Bismuth Subsalicylate—Rash—Doxorubicin—uterine cancer	0.000343	0.000946	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Doxorubicin—uterine cancer	0.000343	0.000945	CcSEcCtD
Bismuth Subsalicylate—Headache—Doxorubicin—uterine cancer	0.000341	0.00094	CcSEcCtD
Bismuth Subsalicylate—ALB—Folate Metabolism—MTHFR—uterine cancer	0.000332	0.00467	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—uterine cancer	0.000331	0.00465	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—uterine cancer	0.000329	0.00462	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—MTHFR—uterine cancer	0.000326	0.00458	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Doxorubicin—uterine cancer	0.000323	0.000892	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—CCL2—uterine cancer	0.000321	0.00452	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Biological oxidations—CYP19A1—uterine cancer	0.00032	0.00449	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Vitamin B12 Metabolism—CCL2—uterine cancer	0.000319	0.00449	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—uterine cancer	0.000317	0.00446	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.000306	0.0043	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—EP300—uterine cancer	0.000291	0.00408	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.000279	0.00392	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.000279	0.00392	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	0.000277	0.0039	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—uterine cancer	0.000275	0.00387	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	0.000272	0.00382	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—NRAS—uterine cancer	0.000272	0.00382	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—MTHFR—uterine cancer	0.000264	0.00371	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—CCL2—uterine cancer	0.00026	0.00365	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—uterine cancer	0.000259	0.00364	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	0.000257	0.00361	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—CCL2—uterine cancer	0.000255	0.00359	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.000248	0.00348	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	0.000234	0.00329	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	0.000233	0.00328	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—CDKN2A—uterine cancer	0.000231	0.00324	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—AKT1—uterine cancer	0.000222	0.00312	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.000221	0.00311	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.000221	0.00311	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	0.000209	0.00294	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—CCL2—uterine cancer	0.000206	0.0029	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.000205	0.00288	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—CDKN1B—uterine cancer	0.000204	0.00287	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—CCL2—uterine cancer	0.000202	0.00284	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	0.000199	0.0028	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—EP300—uterine cancer	0.000189	0.00266	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—EP300—uterine cancer	0.000179	0.00252	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—VEGFA—uterine cancer	0.000179	0.00252	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.000179	0.00252	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.000179	0.00252	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—NRAS—uterine cancer	0.000177	0.00249	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—SRD5A2—uterine cancer	0.000172	0.00241	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—NDUFB11—uterine cancer	0.000172	0.00241	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.00017	0.00239	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—NRAS—uterine cancer	0.000168	0.00236	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	0.000167	0.00235	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.000162	0.00228	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—CXCL8—uterine cancer	0.000159	0.00224	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	0.000158	0.00221	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	0.000156	0.00219	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—CDKN1B—uterine cancer	0.000156	0.00219	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—KRAS—uterine cancer	0.000153	0.00214	CbGpPWpGaD
Bismuth Subsalicylate—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—uterine cancer	0.000147	0.00207	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—KRAS—uterine cancer	0.000145	0.00203	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet degranulation—VEGFA—uterine cancer	0.000143	0.00201	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—PIK3CA—uterine cancer	0.00014	0.00197	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—SRD5A2—uterine cancer	0.000136	0.00192	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—NDUFB11—uterine cancer	0.000136	0.00192	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—uterine cancer	0.000136	0.00192	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—TP53—uterine cancer	0.000136	0.00191	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	0.000132	0.00186	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	0.000131	0.00185	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—HRAS—uterine cancer	0.00013	0.00182	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—AKR1B10—uterine cancer	0.000127	0.00178	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—TP53—uterine cancer	0.000126	0.00177	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	0.000125	0.00176	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—STAR—uterine cancer	0.000124	0.00175	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—AKR1B1—uterine cancer	0.000124	0.00175	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—HRAS—uterine cancer	0.000123	0.00173	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	0.000123	0.00173	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—AKT1—uterine cancer	0.000114	0.00161	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	0.000114	0.00161	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—IRF1—uterine cancer	0.000111	0.00155	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—NDUFB11—uterine cancer	0.00011	0.00155	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—SRD5A2—uterine cancer	0.00011	0.00155	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	0.000107	0.00151	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	0.000106	0.00149	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—RNF43—uterine cancer	0.000105	0.00147	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	0.000101	0.00142	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	0.0001	0.00141	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—AKR1B1—uterine cancer	9.86e-05	0.00139	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—STAR—uterine cancer	9.86e-05	0.00139	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—TP53—uterine cancer	9.79e-05	0.00138	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	9.75e-05	0.00137	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—POLD1—uterine cancer	9.74e-05	0.00137	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	9.74e-05	0.00137	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	9.3e-05	0.00131	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—AKR1C1—uterine cancer	9.11e-05	0.00128	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	8.81e-05	0.00124	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—AKR1C1—uterine cancer	8.64e-05	0.00121	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—RRM2—uterine cancer	8.12e-05	0.00114	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—AKR1B1—uterine cancer	7.97e-05	0.00112	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—STAR—uterine cancer	7.97e-05	0.00112	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—DCN—uterine cancer	7.89e-05	0.00111	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	7.88e-05	0.00111	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—POLD1—uterine cancer	7.73e-05	0.00109	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	7.49e-05	0.00105	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—DCN—uterine cancer	7.47e-05	0.00105	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CYP11A1—uterine cancer	7.43e-05	0.00104	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—AKR1C1—uterine cancer	7.23e-05	0.00102	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—AKR1C3—uterine cancer	7.02e-05	0.000986	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	6.88e-05	0.000967	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	6.66e-05	0.000936	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—AKR1C3—uterine cancer	6.65e-05	0.000935	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HMGA1—uterine cancer	6.48e-05	0.000911	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—RRM2—uterine cancer	6.45e-05	0.000907	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	6.34e-05	0.000892	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—DCN—uterine cancer	6.26e-05	0.00088	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—POLD1—uterine cancer	6.26e-05	0.00088	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—FBXW7—uterine cancer	5.93e-05	0.000833	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CYP11A1—uterine cancer	5.9e-05	0.000829	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—AKR1C1—uterine cancer	5.85e-05	0.000823	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	5.62e-05	0.00079	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—AKR1C3—uterine cancer	5.57e-05	0.000783	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—STK11—uterine cancer	5.47e-05	0.000768	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CYP19A1—uterine cancer	5.47e-05	0.000768	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—RRM2—uterine cancer	5.22e-05	0.000733	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.13e-05	0.000721	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—DCN—uterine cancer	5.06e-05	0.000712	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	4.95e-05	0.000696	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.89e-05	0.000688	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CYP11A1—uterine cancer	4.77e-05	0.000671	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CDKN2B—uterine cancer	4.64e-05	0.000653	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—AKR1C3—uterine cancer	4.51e-05	0.000633	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CYP19A1—uterine cancer	4.34e-05	0.00061	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—STK11—uterine cancer	4.34e-05	0.00061	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—SMAD3—uterine cancer	4.24e-05	0.000596	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—MTHFR—uterine cancer	4.11e-05	0.000577	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	4.07e-05	0.000573	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—AKT1—uterine cancer	4.05e-05	0.000569	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—FGFR2—uterine cancer	4.04e-05	0.000569	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MTHFR—uterine cancer	3.89e-05	0.000547	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	3.88e-05	0.000546	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.62e-05	0.000509	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CYP19A1—uterine cancer	3.51e-05	0.000494	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—STK11—uterine cancer	3.51e-05	0.000494	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—EP300—uterine cancer	3.45e-05	0.000485	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.3e-05	0.000463	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—VEGFA—uterine cancer	3.27e-05	0.00046	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—MTHFR—uterine cancer	3.26e-05	0.000458	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—NRAS—uterine cancer	3.23e-05	0.000454	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—EP300—uterine cancer	3.14e-05	0.000442	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.87e-05	0.000404	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—KRAS—uterine cancer	2.78e-05	0.000391	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—MTHFR—uterine cancer	2.64e-05	0.000371	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PIK3CA—uterine cancer	2.55e-05	0.000359	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—ERBB2—uterine cancer	2.54e-05	0.000357	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—TP53—uterine cancer	2.47e-05	0.000347	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—HRAS—uterine cancer	2.36e-05	0.000332	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CDKN1B—uterine cancer	2.35e-05	0.000331	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.32e-05	0.000327	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PTEN—uterine cancer	2.28e-05	0.000321	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CTNNB1—uterine cancer	2.22e-05	0.000312	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—EP300—uterine cancer	2.18e-05	0.000306	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PTEN—uterine cancer	2.17e-05	0.000304	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—AKT1—uterine cancer	2.09e-05	0.000293	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—EP300—uterine cancer	2.07e-05	0.00029	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—NRAS—uterine cancer	1.93e-05	0.000272	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PTEN—uterine cancer	1.81e-05	0.000255	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—EP300—uterine cancer	1.73e-05	0.000243	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—KRAS—uterine cancer	1.66e-05	0.000234	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PIK3CA—uterine cancer	1.61e-05	0.000227	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PIK3CA—uterine cancer	1.53e-05	0.000215	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PTEN—uterine cancer	1.47e-05	0.000206	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HRAS—uterine cancer	1.41e-05	0.000199	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—EP300—uterine cancer	1.4e-05	0.000197	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—AKT1—uterine cancer	1.32e-05	0.000185	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PIK3CA—uterine cancer	1.28e-05	0.00018	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—AKT1—uterine cancer	1.25e-05	0.000175	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—AKT1—uterine cancer	1.05e-05	0.000147	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PIK3CA—uterine cancer	1.04e-05	0.000146	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—AKT1—uterine cancer	8.46e-06	0.000119	CbGpPWpGaD
